Decreases pitolisant exposure by 50%, potentially reducing efficacy. Dosage adjustment required.
Source: NLP:pitolisant hydrochloride
Brand names: Wakix
Route: Oral
Contraindications
4 CONTRAINDICATIONS WAKIX is contraindicated in patients with: known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported in patients treated with WAKIX [see Adverse Reactions ( 6.2 )] . severe hepatic impairment. WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate hepatic impairment [see Use in Specific Populations ( 8.6 )] . Known hypersensitivity to pitolisant or any component of the formulation ( 4 ) Severe hepatic impairment ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460. Risk Summary Available case reports from clinical trials and postmarketing reports with WAKIX use in pregnant women have not determined a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproductive studies, administration of pitolisant during organogenesis caused maternal and embryofetal toxicity in rats and rabbits at doses ≥13 and >4 times the maximum recommended human dose (MRHD) of 35.6 mg based on mg/m 2 body surface area, respectively. Oral administration of pitolisant to female rats during pregnancy and lactation adversely affected maternal and fetal health and produced developmental delay at doses ≥13 times the MRHD, based on mg/m 2 body surface area and increased the incidence of major malformations at 22 times the MRHD (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Pitolisant was administered orally to pregnant rats during the period of organogenesis at doses of 30, 52, 90 and 110 mg/kg/day, which are approximately 7, 13, 22 and 27 times the MRHD, based on mg/m2 body surface area, respectively. Maternal toxicity occurred at >22 times the MRHD and included convulsions and decreases in body weight and food consumption. At these maternally toxic doses, no adverse effects on embryofetal development were n
6 interactions on record
Decreases pitolisant exposure by 50%, potentially reducing efficacy. Dosage adjustment required.
Source: NLP:pitolisant hydrochloride
Concomitant use may add to QT effects and increase risk of cardiac arrhythmia. Avoid combination.
Source: NLP:pitolisant hydrochloride
Concomitant administration increases pitolisant exposure by 2.2-fold. Reduce WAKIX dose by half.
Source: NLP:pitolisant hydrochloride
Hormonal contraceptive effectiveness may be reduced during and for 21 days after WAKIX discontinuation. Use alternative non-hormonal contraceptive.
Source: NLP:pitolisant hydrochloride
Centrally acting H1 receptor antagonists may reduce WAKIX effectiveness. Avoid centrally acting H1 receptor antagonists.
Source: NLP:pitolisant hydrochloride
WAKIX may reduce effectiveness of sensitive CYP3A4 substrates including hormonal contraceptives.
Source: NLP:pitolisant hydrochloride